Search results
Your search for FMC7 returned no results
Showing 101 to 150 of 475 results for face
Showing 101 to 150 of 475 results for face
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.
Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.
New tests could spare people with early breast cancer from unnecessary chemotherapy
More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)
Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)
Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
Digital technologies for managing non-specific low back pain: early value assessment (HTG712)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.
Adults with depression who want to quit antidepressants should be given support
Adults with depression who want to stop taking antidepressants should have the dose of their medication reduced in stages to reduce the likelihood and severity of withdrawal symptoms, NICE has said.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Working in partnership to harness the potential of digital technology
Nicola Bent talks about NICE and the AHSN Network’s important ambition to address market access challenges for digital innovation as part of the collaboration agreement.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Devices for remote monitoring of Parkinson's disease (HTG657)
Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.
Jeanette Kusel explains how we are working in partnership to improve patient access to the best digital health innovations.
This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.
View quality statements for QS130Show all sections
Sections for QS130
People who have had a stroke should be offered additional rehabilitation
People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover
Digital services to enable easier access to weight management support
Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England
New treatment for cardiovascular disease could benefit millions
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
Around 100,000 fewer colonoscopies expected to take place each year
Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.
Two technologies to provide digital services for people with COPD
More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.
Hundreds of children with type 2 diabetes to be offered choice of two life changing technologies
Children with type 2 diabetes who currently manage their condition with the stressful task of finger prick testing several times a day could be offered a choice between two ‘life changing’ technologies to virtually automate the process.
Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety or low mood have been recommended for use in the NHS.
NICE recommends 8 digitally enabled therapies to treat depression and anxiety
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance.
More people could be treated out of hospital in the NHS's new respiratory hubs and virtual wards
Consultation launched on draft guidance for the assessment and management of acute respiratory infections in people over 16
NICE partners with international health technology assessment bodies
Six health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
NICE to become single point of access for Covid-19 guidance and advice
NICE announced that it is to host a new, single point of advice on caring for people with Covid-19 and the management of Covid-19 in a variety of clinical settings.
NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.
Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)
Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.
Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.
This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.
View quality statements for QS210Show all sections
Sections for QS210
- Quality statements
- Quality statement 1: Documented initial assessment
- Quality statement 2: Prescribing antimicrobials
- Quality statement 3: Antibiotic duration
- Quality statement 4: Information about acute respiratory infection virtual wards
- Quality statement 5: Multidisciplinary team
- Quality statement 6: Support to self-manage on a virtual ward
- Quality statement 7: Virtual ward discharge summaries
Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.
This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.
Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)
Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.